source
- Leerink analyst downgrades Bristol Myers over pipeline concernsA Leerink analyst signaled new bearishness on Bristol Myers Squibb, downgrading the company's stock rating. Analyst David Risinger moved the rating from outperform to a lower stance, saying he is…
- Genmab reports 45.9% response rate for FRα‑directed ADC in platinum‑resistant ovarian cancer; Lilly expands Jaypirca labelGenmab presented new data on its FRα‑targeted antibody‑drug conjugate Rina‑S in patients with platinum‑resistant ovarian cancer. In the trial, the ADC achieved an objective response rate of 45.9%,…